bronchiectasis
BRONCHIECTASIS
Bronchiectasis is an irreversible pathologic dilatation or ectasia of the bronchi due to repeated airway infection and inflammation.
It enhances susceptibility to bronchial infection and increases inflammatory reaction which causes further lung damage.
Classic symptoms of of bronchiectasis are cough with chronic sputum production along with recurring infective exacerbations and hemoptysis.

Bronchiectasis Drug Information

Drug Information

Indication: Reduction of sputum viscosity.

Indication: Otitis media, upper & lower resp tract infections, UTI including pyelonephritis, cystitis, gonococcal uret...

Indication: Upper & lower resp tract, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicated gonococc...

Indication: Uncomplicated & complicated resp tract infections; otitis media & sinusitis. Eyes, kidneys &/or ef...

Indication: Resp disorders associated w/ viscid mucus.

Indication: Resp tract, ENT, GI, biliary tract, ocular, skin & soft tissue, bone & joint, O&G, oral, dental or...

Indication: Skin & skin structure, acute & chronic resp, complicated & uncomplicated, acute & chronic GUT ...

Indication: Resp disorders associated w/ viscid or excessive mucus.

Indication: Expectorant for symptomatic relief of cough due to colds & upper resp tract infections.

Indication: Upper & lower resp tract, GUT, ENT, skin & soft tissue, bone & joint infections, UTI, O&G infe...

2  /  16
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 15 hours ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
5 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
5 days ago
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.